Skip to content

Travere Therapeutics, Inc. TVTX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

LQD
Liquidia CorporationLQDA
$2.78M+441%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$1.18M-107%
Scholar Rock logo
Scholar RockSRRK
$2.04M-70.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.13B+72.3%
Enterprise value$5.07B+65.5%
P/S9.6×-1.3×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets?
Travere Therapeutics, Inc. (TVTX) reported increase (decrease) in prepaid expense and other assets of $6.38M in Q1 2026.
How has Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets changed year-over-year?
Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets increased by 282.2% year-over-year, from $1.67M to $6.38M.
What is the long-term trend for Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets?
Over 2 years (2022 to 2025), Travere Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets has grown at a 24.9% compound annual growth rate (CAGR), from $5.2M to $8.1M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.